---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-015144"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:55:15.686295+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q3 net loss $8.5M ($0.47/sh); cash $159.6M; IND for IMM-1-104 in Q1 2022

## Summary
- Net loss attributable to common stockholders $8.5M vs $4.4M in Q3 2020; diluted EPS $(0.47).
- Cash and marketable securities $159.6M as of Sep 30, 2021, up from $37.1M at Dec 31, 2020.
- Completed upsized IPO of 8.625M shares at $15.00 each, gross proceeds $129.4M.
- IND filing for dual-MEK inhibitor IMM-1-104 expected Q1 2022; Phase 1 trial in 1H 2022.
- R&D expenses $6.2M (up from $4.1M); G&A $2.6M (up from $0.7M) due to IPO prep and headcount.

## SEC filing metadata
- accession: 0001558370-21-015144
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000155837021015144/0001558370-21-015144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000155837021015144/imrx-20211109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-015144
- JSON: https://secwatch.observer/filing/0001558370-21-015144.json
- Plain text: https://secwatch.observer/filing/0001558370-21-015144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.